Shots:

• The launch of generic oncology therapy Gefitinib will follow the loss of market exclusivity of the reference product with the already expired patent protection
• The Gefitinib is listed in national essential medicines for cancer- indicated to treat LA or m-NSCLC with activating mutations of EGFR-TK and will be available in 13 EU countries with its expected availability in other countries
• Gefitinib (qd) is a non-CT therapy- recommended by ESMO as 1L therapy for EGFR-activating mutation metastatic NSCLC and has received European regulatory approval for the generic molecule in July’18

Click here to read full press release/ article | Ref: Novartis | Image: Behance